

## Trial Protocol

1 **TITLE: YOGA FOR CHRONIC LOW BACK PAIN IN EHP**

2

3 **RUNNING/ABBREVIATED TITLE: YOGA FOR CLBP IN EHP**

4

5 **Principal Investigator (P.I.):**

6 Robert B. Saper, M.D., M.P.H.

7 Chair, Department of Wellness & Preventive Medicine

8 Primary Care Institute

9 [saperr@ccf.org](mailto:saperr@ccf.org)

10 216-448-4325

11

12

13

14

## Trial Protocol

### 15 STUDY OVERVIEW

16

17 This study uses clinical trial and implementation science methodology to specifically assess the  
18 clinical effectiveness and implementation of yoga into the management of chronic low back  
19 pain (cLBP) within the Cleveland Clinic (CC) Employee Health Plan (EHP). We will use a Type 1  
20 hybrid effectiveness-implementation study design,<sup>23</sup> which tests the effectiveness of a clinical  
21 intervention while collecting data on implementation.

22

#### 23 **Specific Aims:**

24

25 **Aim 1: Conduct a randomized controlled trial to determine the clinical effectiveness of a 12-**  
26 **week virtual yoga intervention (Yoga Now) compared to a wait-list control group (Yoga Later)**  
27 **for cLBP in the CC Employee Health Plan population.** We hypothesize that at 12 weeks the  
28 Yoga Now group will have clinically and statistically significant improvements in pain and  
29 function compared to the Yoga Later group.

30

31 *Co-primary outcomes* will be self-reported average pain intensity for the previous week (11-  
32 point numerical rating scale ranging from 0=no pain to 10=worst possible pain) and back-  
33 related function (modified Roland Morris Disability Questionnaire ranging from 0=no functional  
34 impairment to 23=worst impairment of function). *Secondary outcomes* will include analgesic  
35 use, global improvement, and overall satisfaction. Yoga participants will receive a reproducible  
36 standardized weekly yoga intervention delivered virtually with additional resources for home  
37 practice. The wait-list control participants will receive usual back pain care. Data collection will  
38 occur at baseline, 6 weeks, 12 weeks, and 24 weeks. The primary time point of interest will be  
39 12 weeks. After the 24-week study period the wait-list control group will be offered the same  
40 protocol but in a non-study format without additional data collection.

41

42 **Aim 2: Use mixed methods to measure implementation outcomes and assess facilitators and**  
43 **barriers to yoga's implementation in the CC EHP setting.** We hypothesize that implementation  
44 of yoga in the context of a RCT in CC EHP will be successful and facilitated by the partnership  
45 with EHP for recruitment and virtual intervention.

46

47 Study record tracking will be used to measure feasibility (e.g., rate of recruitment, loss-to-  
48 follow up) and intervention costs (e.g., yoga instructors, yoga mats). Study staff observation of  
49 classes using a checklist will assess fidelity of the intervention to the standardized yoga  
50 protocol. Acceptability, appropriateness, and adoption of yoga for cLBP will be assessed  
51 through quantitative measures (satisfaction, home practice logs) and open-ended questions to  
52 participants in surveys (Yoga Now Questionnaire Supplements, Weeks 12 and 24).

53

54 **Aim 3 (Exploratory): Demonstrate the feasibility of evaluating cost-effectiveness of yoga**  
55 **compared to usual care for cLBP from the perspective of the payer.**

56

## Trial Protocol

57 Cost of implementing the intervention will be measured. Total and back-related medical  
58 expenditures for the six-month study period will be compared between the yoga and wait-list  
59 control groups. We hypothesize that total and back-related medical expenditures by CC EHP for  
60 the yoga group will be less than the usual care group.

61

### 62 **BACKGROUND**

63 **Low back pain (LBP)** is common with enormous impact on patient suffering, healthcare cost,  
64 and provider burden.<sup>1</sup> Up to 80% of U.S. adults will experience at least one episode of LBP in  
65 their lifetime.<sup>2</sup> Chronic LBP affects roughly 10% of U.S. adults.<sup>2</sup> The prevalence of LBP globally  
66 has increased from 377.5 million in 1990 to 577.0 million in 2017, and is the leading cause of  
67 disability worldwide.<sup>26, 27, 28</sup> LBP is the second most common reason for doctor visits.<sup>27,1</sup> The  
68 morbidity and cost of LBP, especially chronic LBP, is particularly high due to comorbid pain (e.g.,  
69 neck pain, osteoarthritis, fibromyalgia, headache) and mental health conditions (e.g.,  
70 depression, anxiety, PTSD). Back pain is a financial burden on society, families, and individuals.  
71 Back and neck pain in 2016 ranked highest in U.S. health expenditures (\$134.5 billion) - higher  
72 than diabetes, ischemic heart disease, and depression.<sup>3</sup> Patients and their families bore 9.2%  
73 (\$12.4 billion) of these costs. Despite a national trend for increased spending on LBP, worsening  
74 outcomes have been observed at the population level, including increasing levels of disability.<sup>4</sup>

75

76 **Treatment of LBP.** A clear gap has been identified between the evidence base and real world  
77 treatment of LBP nationally and at CC. Clinical guidelines from the American College of  
78 Physicians (ACP) issued in 2017 for acute and chronic LBP recommend non-pharmacologic  
79 approaches should be used first, non-opioid medications second, and thereafter opioid  
80 medications only if benefits clearly outweigh the risks.<sup>5</sup> ACP guidelines recommend  
81 acupuncture, massage, spinal manipulation, and superficial heat for acute LBP. For cLBP, yoga,  
82 spinal manipulation, exercise (PT), acupuncture, massage, mindfulness, cognitive behavioral  
83 therapy (CBT), and others are recommended. This stepped care approach is based on AHRQ  
84 systematic reviews<sup>6</sup> and supported by guidelines from the HHS Pain Management Best  
85 Practices Inter-Agency Task Force.<sup>31</sup> Meta-analyses of trials utilizing yoga and mindfulness  
86 therapies also demonstrate potential to reduce opioid use.<sup>7</sup> Economic evaluations suggest  
87 group interventions such as yoga can be cost saving.<sup>8</sup>

88

89 Despite the evidence and guidelines, it is unusual for cLBP patients to receive recommended  
90 non-pharmacologic treatments in health care systems, including CC. Causes are multiple and  
91 include lack of reimbursement, licensed providers, awareness, and adequate time for busy  
92 clinicians to counsel patients about options and shared decision making. As a result,  
93 medications and in particular opioids are often prescribed, despite minimal evidence for their  
94 effectiveness.<sup>9</sup> Back pain is the most common non-cancer diagnosis associated with opioid  
95 prescribing.<sup>29</sup> Pain is a major upstream driver of opioid use disorder, overdose, and death.  
96 Almost 5% of individuals receiving opioid prescriptions go on to misuse or addiction, with the  
97 most commonly reported motivation for opioid misuse being the relief of pain.<sup>11</sup> Almost half of  
98 persons who use heroin and/or fentanyl report their addiction began with prescription opioids.

## Trial Protocol

99 Thus, studying and implementing evidence-based non-pharmacologic interventions is an  
100 important strategy for improving pain management and reducing opioid use disorder.

101

### 102 **STUDY DESIGN & METHODS**

103 We will use a single-blinded (investigator) two-arm randomized control trial (RCT) design. The  
104 trial will be 24 weeks long and divided into two distinct parts: an initial 12-week Treatment  
105 Phase followed by a 12-week Follow-up Phase. Participants will be randomized 1:1 into weekly  
106 virtual yoga classes (***Yoga Now***) or a wait-list control (***Yoga Later***) who will receive usual care.  
107 After the 24-week study period, participants in Yoga Later will be offered the yoga intervention  
108 in a non-study format.

109

#### 110 **Study Participants:**

111 Participants will be recruited from members of the Cleveland Clinic Employee Health Program  
112 (CC EHP). There are approximately 105,000 members, including caregivers and their families,  
113 across Northeast Ohio, Florida, and Las Vegas.

114

#### 115 ***Inclusion criteria:***

- 116 • 18-64 years old
- 117 • Current non-specific LBP persisting  $\geq 12$  weeks with average pain intensity  $\geq 4$  for the  
118 previous week on an 11-point numerical rating scale
- 119 • Ability to speak and understand English
- 120 • Agrees to be visualized by yoga instructors and other participants in virtual yoga sessions

121

#### 122 ***Exclusion criteria:***

- 123 • Any severe psychiatric or medical comorbidity in the PI's judgment that would make  
124 study participation unsafe or not feasible.

125

#### 126 **Recruitment, Eligibility Screening, Enrollment, and Randomization**

127 The office of CC Employee Health Plan will generate a list of potential participants ages 18-64  
128 with a billing or ordering diagnosis of LBP (ICD-10 M54.5) in the last three years. CC EHP will  
129 then directly mail each potential participant identified a recruitment letter (*attached*) inviting  
130 the potential participant to contact the study team to learn more about the study. When an  
131 interested participant responds affirmatively in response to the recruitment letter by phone or  
132 e-mail, the study team member will communicate with the potential participant to perform a  
133 pre-screening interview (*attached*) for eligibility and assessment of the person's interest in  
134 participation. Interested participants will then be sent an Information Sheet (*attached*) in lieu of  
135 written consent via the participant's preferred method (e.g., e-mail, USPS or MyChart). The  
136 study team member will arrange a follow up call or IT approved, HIPAA-secure, virtual meeting  
137 with the person to re-confirm the participant's interest, confirm eligibility and review the study  
138 Information Sheet line by line allowing adequate time for questions about the study and  
139 assuring participant understanding through the "teach back" method. If the person verbally  
140 agrees to participate, the participant will complete a baseline survey via the participant's

## Trial Protocol

141 preferred method (e.g., e-mail, USPS or MyChart) and subsequently randomize the participant  
142 to virtual yoga group or wait-list group. Participants will be informed that web links to virtual  
143 classes and to pre-recorded yoga classes will be sent to their specified e-mail address. The  
144 participant will be asked permission for instructors and other participants to view them during  
145 their virtual class. They will be asked to maintain the privacy and confidentiality of any  
146 comments made by others during class. They will also be asked their preferred method for  
147 follow-up communication going forward (e.g., e-mail, USPS, MyChart). The participant's  
148 preferred method will be used for follow-up questionnaires, and completion of yoga home  
149 practice logs. All study questionnaires will be stored in REDCap.

150 Information about the study will also be included in general newsletters, websites, other  
151 communications, and social media platforms that EHP and Cleveland Clinic use to target their  
152 employees and family members. We will use the Recruitment Flyer as advertisement in the  
153 following platforms:

- 154 • Internal websites of Cleveland Clinic: Intranet, DocCom, Connect Today
- 155 • EHP Website (<https://employeehealthplan.clevelandclinic.org/>)
- 156 • EHP newsletters, letters, and emails
- 157 • CC Corporate communications emails that are targeted to caregivers only (e.g., Caregiver  
158 Communications, Employee Wellness)
- 159 • CC employee designated areas, e.g., nurses' lounges, as approved by administration for  
160 identified area
- 161 • Social Media: CC Employee Facebook Page (closed group)

162  
163 Members of the study team will also provide information about the study at routine clinical and  
164 employee meetings across the enterprise. If an interested person responds to either of these  
165 alternative methods, the same recruitment process will be followed. Study team members will  
166 routinely send EHP a list of enrolled participants to avoid redundant EHP recruitment mailings.

167 Screening and enrollment processes will all occur remotely and involve the following: (1) A  
168 telephone or IT approved, HIPAA-secure, virtual meeting platform where participants provide  
169 verbal consent for completion of eligibility screening through a standardized questionnaire; (2)  
170 if eligible, provision of information about the study with use of an IRB approved Information  
171 Sheet in lieu of informed consent with signature, answering all questions about the study, and  
172 assuring participant understanding through the "teach back" method.

173 Randomization occurs after administering the baseline survey (see Table 1 Data Collection  
174 Schedule). We will use a computerized randomization procedure built into our study  
175 management system, REDCap, to randomize each enrolled participant using a 1:1 ratio to yoga  
176 or wait-list control. Permuted variably-sized block randomization with block sizes of 6, 12 and  
177 18 will be used.

178 **Intervention and Comparator:**

## Trial Protocol

179 The study interventions start within approximately one week of baseline data collection and  
180 randomization. All participants throughout the entire 24-week study can continue to receive  
181 routine medical care including doctor visits and pain medication as prescribed.

182

183 The **hatha yoga intervention** is structured and reproducible. The full instructor manual and  
184 participant manual are available as hardcopy and online.<sup>24</sup> Originally, it was developed by an  
185 expert panel led by Rob Saper, MD MPH in 2007 and used in a pilot study of 30 participants  
186 with cLBP.<sup>16</sup> It was further refined in 2011 in a dosing study of 95 participants<sup>17</sup> and a larger  
187 non-inferiority trial of 320.<sup>18</sup> It is designed specifically for the yoga-naïve individual for  
188 effectiveness and safety in cLBP. Each class is 60 minutes long and will be delivered virtually to a  
189 maximum class size of 20. Yoga instructors will complete an 8-hour training on the protocol  
190 directed by our CC lead yoga therapist Judi Barr, E-RYT 500, C-IAYT. It begins with a relaxation  
191 exercise, yoga breathing exercises, and a brief discussion of yoga philosophy. The class  
192 proceeds with warm-up yoga exercises and then yoga postures. Yoga breathing is emphasized  
193 throughout each class. The class ends with a relaxation exercise. The 12 weeks are divided into  
194 four 3-week segments. Each segment is given a theme (e.g., “*Listening to the Wisdom of the*  
195 *Body*”). Participants are frequently advised to go slowly and carefully. The degree of difficulty of  
196 postures learned increases with each segment. For each segment, the participants gradually  
197 learn a sequence of 12–15 poses. The protocol provides variations and uses various aids (e.g.,  
198 chair, strap) to accommodate a range of physical abilities. Participants are strongly encouraged  
199 to practice at home for 30 minutes daily on days which they do not attend yoga class. To  
200 facilitate home practice, participants will be given a free yoga mat, participant manual, and  
201 provided access to Webex, virtual classes led by the study instructors. Classes will be overseen  
202 by Cleveland Clinic’s IT Video Conferencing team to manage the focus in ‘Webex Layout’ to view  
203 only instructor activity (PIN instructors to their activity stage) during class and mute participants  
204 during class time. Webex pre-recorded class links for participant practice between live classes  
205 will be stored on a secure Cleveland Clinic server for ‘Videos on Demand,’ which is an externally  
206 accessible, unlisted link that will be password protected. A study member will provide the  
207 password for the class link to specific class participants to view for weekly practice using  
208 participant registration captured in REDCap. Ten percent of online yoga classes will be reviewed  
209 for fidelity to the protocol using a checklist. A 12-week follow-up phase consisting of larger  
210 optional classes for maintenance will follow.

211

212 Individuals randomized to the wait list control will be offered non-study yoga classes after 24-  
213 weeks. They will also receive a free yoga mat and access to pre-recorded online videos.

214

215

216

217

218

219

220

221

## Trial Protocol

222 **Table 1: Data Collection Schedule**

223

<b>Data Collection</b>	<b>Eligibility Screening</b>	<b>Baseline</b>	<b>Week 6</b>	<b>Week 12</b>	<b>Week 24</b>
Eligibility Screening	<b>X</b>				
Low Back Pain History		<b>X</b>			
Sociodemographics		<b>X</b>			
Pain Intensity		<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>
Roland-Morris Disability Scale		<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>
Pain Interference		<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>
Pain Medications		<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>
Satisfaction with Care		<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>
Global Improvement			<b>X</b>	<b>X</b>	<b>X</b>
Adverse Effects			<b>X</b>	<b>X</b>	<b>X</b>
Home Practice*			<b>X</b>	<b>X</b>	<b>X</b>

224  
225                   \* Weekly diary for participants taking yoga classes

226  
227  
228

229 **Outcome Measures**

230 The co-primary outcome measures are (1) average pain intensity in previous week on an 11-  
231 point numerical rating scale where 0 is no pain and 10 is the worst pain possible, and (2) back-  
232 related function using the 23-point modified Roland Morris Disability Questionnaire (RMDQ).  
233 The main time point of interest is 12 weeks. Secondary outcomes include analgesic pain  
234 medication. This will be collected using several methods: (1) Self-report of all prescription and  
235 over the counter pain medications taken in the previous week including dosages and  
236 frequencies. (2) Mean morphine milligram equivalents (MME) taken per day per patient over  
237 the previous three months based on filled prescriptions, available through the EHP prescription  
238 database. Additional secondary outcomes include overall improvement by self-report (6-point  
239 Likert scale, 0 = very worse to 6 = very improved) and pain interference.

240  
241 Implementation outcomes derived from study records will include rate of recruitment,  
242 proportion enrolled of total population contacted, attendance to yoga classes, home practice,  
243 study retention, missing data, and intervention costs. Acceptability will be measured by  
244 participant satisfaction with treatment (5-point Likert scale, 0 = very dissatisfied to 5 = very  
245 satisfied) and answers to open-ended questions about the effect of yoga, facilitators, and  
246 barriers. EHP will assist gathering utilization and medical expenditure data (admissions, visits,  
247 imaging, procedures, and total and back-specific costs of care). Adverse events will be collected  
248 from questionnaires and direct reports to study staff.

249  
250  
251

## Trial Protocol

### 252 **Data Analysis**

253 The primary analysis will follow the intention-to-treat principle. Baseline characteristics will be  
254 summarized with appropriate descriptive statistics and will be compared between the two  
255 groups using t-test, Wilcoxon rank sum test, or chi-squared test as appropriate. Linear mixed-  
256 effects models will be used to analyze the co-primary outcomes, changes in pain numerical  
257 rating scale and the modified Roland Morris Disability Questionnaire. Each model will include  
258 time, group, their interaction, and baseline score. Any potential subject characteristics with  
259 significant differences at baseline will also be included in the model as potential confounders. A  
260 random intercept at the subject level will be included to account for the clustered data  
261 structure. Based on the model, the primary comparison will be the change from baseline  
262 between the two groups at week 12. Comparisons at other time points will be considered as  
263 secondary.

264

265 We will also perform multiple sensitivity analyses. A per-protocol analysis will be performed by  
266 replacing the binary group indicator with the number of yoga sessions attended (0 for the  
267 control participants and the exact number of classes attended by the yoga participants).  
268 Missing data are assumed missing at random in the primary analyses. We will also perform  
269 multiple imputation and analyze the imputed data.

270

271 **Secondary outcomes** will be analyzed similarly as above. Dichotomous or ordinal outcomes will  
272 be analyzed using generalized linear mixed-effects models. Adverse events will be summarized  
273 as frequencies and percentages and compared using the chi-squared test. All analyses will be  
274 conducted in R-studio (Boston, MA).

275

276 **Sample size and power calculations.** We assumed a minimal clinically significant decrease in  
277 pain intensity and Roland Morris based on the literature as 2.0 and 3.0 points, respectively.  
278 Standard deviations for these two outcomes based on previous studies are approximately 2.0  
279 and 5.0, respectively. Given the two co-primary outcomes we will use an alpha=0.025. A  
280 conservative 20% attrition rate was assumed. We assumed no change in the control group.  
281 Given these parameters, a total sample size of 140 participants is estimated to provide  
282 99% and 82% statistically and clinically significant differences in pain intensity and Roland  
283 Morris, respectively.

284

285 **Implementation outcomes** such as recruitment rates, yoga class attendance, home practice,  
286 study retention, missing data, implementation costs, and participant satisfaction will be  
287 summarized with descriptive statistics. Change in satisfaction between the Yoga Now and Yoga  
288 Later groups will be analyzed as described above for secondary outcomes. Responses to open-  
289 ended questions about the effect of yoga, facilitators and barriers will be analyzed using rapid  
290 thematic analysis.<sup>25</sup>

291

292 The Principal Investigator will identify and invite up to two (2) employees from the Clinic  
293 Diversity Office to complete scripted interviews conducted by study team members. The  
294 purpose of this interview is to understand if our study was representative of the Cleveland



## Trial Protocol

295 Clinic employee health plan population and to better understand barriers when working within  
296 an employee population.

297

298 Up to four (4) interviews will be conducted by study personnel with yoga study instructors as  
299 related to their experience as instructors. The purpose of this is to understand what challenges  
300 they had while conducting the study and how to facilitate those challenges in future remote  
301 studies.

302

303 All interviews will be conducted and recorded via the secure Cleveland Clinic Team's app at  
304 which time the interviewees will be verbally consented to agree to being recorded. Recordings  
305 will be deleted after analysis is completed.

306

307 Cost-benefit from the perspective of the payer will be conducted by comparing incremental  
308 costs of the Yoga Now group compared to the Yoga Later group over the 24-week study period.  
309 For Yoga Now, the incremental costs will only include direct medical costs (direct intervention  
310 costs plus ongoing direct medical utilization costs). For the Yoga Later, it will be only direct  
311 medical utilization costs. Combined LBP and non-LBP-related healthcare utilization will be used  
312 for all of these analyses. Sensitivity analyses using LBP-related utilization only will also be  
313 performed. All cost effectiveness analyses will use the ITT principle.

314

315 We will compare aggregate demographic and socio demographics information on the entire  
316 employee health population (EHP) for comparisons with aggregate data of the study population  
317 to see if they are representative of the EHP population in age, gender, race, level of education,  
318 and employment status. We will use chi-square analysis to determine if there are significant  
319 differences between the employee population and our study sample. We will not document  
320 this information in REDCap and we will not report individual data.

321

322

### 323 **Table 2. EHP Data Collection**

324

Demographics & Sociodemographics	For comparison with Study Population
Age	All Age Ranges
Gender	Male / Female
Race	American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other Pacific Islander, White, Other
Level of Education	High School, GED certificate, Technical School, College, Masters, Doctorate
Employment Status	Active vs Non-Active

325

326

327

## Trial Protocol

### 328 **Confidentiality**

329 All study data extracted from EPIC will be de-identified, stored and secured in the Cleveland  
330 Clinic server network. Only the study team will have access to the data, and if shared, using a  
331 password protected Excel spreadsheet PHI that could identify a participant will be removed or  
332 changed before files are shared with other researchers or results are made public. Data  
333 analysts' will not be given access to PHI or other identifiers. Outcomes data will be reported in  
334 aggregate, not by or with personal identifiers. We will follow Cleveland Clinic's strict policies to  
335 maintain privacy and confidentiality. The data will be maintained for a period of 6 years after  
336 completion of the study.

337

### 338 **References**

- 339 1. Hartvigsen J, Hancock MJ, Kongsted A, et al. What low back pain is and why we need to  
340 pay attention. *Lancet*. 2018;391(10137):2356-2367.
- 341
- 342 2. Licciardone JC. The epidemiology and medical management of low back pain during  
343 ambulatory medical care visits in the United States. *Osteopath Med Prim Care*.  
344 2008;2:11.
- 345
- 346 3. Dieleman JL, Cao J, Chapin A, et al. US Health Care Spending by Payer and Health  
347 Condition, 1996-2016. *JAMA*. 2020;323(9):863-884.
- 348
- 349 4. Carey K, Ameli O, Garrity B, et al. Health insurance design and conservative therapy for  
350 low back pain. *Am J Manag Care*. 2019;25(6):e182-e187.
- 351
- 352 5. Qaseem A, Wilt TJ, McLean RM, Forciea MA, Clinical Guidelines Committee of the  
353 American College of P. Noninvasive Treatments for Acute, Subacute, and Chronic Low  
354 Back Pain: A Clinical Practice Guideline from the American College of Physicians.  
355 *Annals of internal medicine*. 2017;166(7):514-530.
- 356
- 357 6. Chou R, Deyo R, Friedly J, et al. Nonpharmacologic Therapies for Low Back Pain: A  
358 Systematic Review for an American College of Physicians Clinical Practice Guideline.  
359 *Ann Intern Med*. 2017;166(7):493-505.
- 360
- 361 7. Garland EL, Brintz CE, Hanley AW, et al. Mind-Body Therapies for Opioid-Treated Pain:  
362 A Systematic Review and Meta-analysis. *JAMA Intern Med*. 2019.
- 363
- 364 8. Herman PM, McBain RK, Broten N, Coulter ID. Update of Markov Model on the Cost  
365 effectiveness of Nonpharmacologic Interventions for Chronic Low Back Pain Compared  
366 to Usual Care. *Spine (Phila Pa 1976)*. 2020;45(19):1383-1385.
- 367
- 368 9. Chou R, Deyo R, Friedly J, et al. Systemic Pharmacologic Therapies for Low Back Pain:

## Trial Protocol

- 369 A Systematic Review for an American College of Physicians Clinical Practice Guideline.  
370 *Ann Intern Med.* 2017;166(7):480-492.  
371
- 372 10. Sherry TB, Sabety A, Maestas N. Documented Pain Diagnoses in Adults Prescribed  
373 Opioids: Results From the National Ambulatory Medical Care Survey, 2006-2015. *Ann*  
374 *Intern Med.* 2018;169(12):892-894.  
375
- 376 11. Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Prescription Opioid Use,  
377 Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and  
378 Health. *Ann Intern Med.* 2017;167(5):293-301.  
379
- 380 12. Sherman KJ, Cherkin DC, Erro J, Miglioretti DL, Deyo RA. Comparing yoga, exercise,  
381 and a self-care book for chronic low back pain: a randomized, controlled trial. *Ann Intern*  
382 *Med.* 2005;143(12):849-856.  
383
- 384 13. Sherman KJ, Cherkin DC, Wellman RD, et al. A randomized trial comparing yoga,  
385 stretching, and a self-care book for chronic low back pain. 2011:2019-2026.  
386
- 387 14. Williams K, Abildso C, Steinberg L, et al. Evaluation of the effectiveness and efficacy of  
388 Iyengar yoga therapy on chronic low back pain. *Spine.* 2009;34(19):2066-2076.  
389
- 390 15. Tilbrook HE, Cox H, Hewitt CE, et al. Yoga for chronic low back pain: a randomized trial.  
391 *Ann Intern Med.* 2011;155(9):569-578.  
392
- 393 16. Saper RB, Sherman KJ, Cullum-Dugan D, Davis RB, Phillips RS, Culpepper L. Yoga for  
394 chronic low back pain in a predominantly minority population: a pilot randomized  
395 controlled trial. *Altern Ther Health Med.* 2009;15(6):18-27.  
396
- 397 17. Saper RB, Boah AR, Keosaian J, Cerrada C, Weinberg J, Sherman KJ. Comparing  
398 once- versus twice-weekly yoga classes for chronic low back pain in predominantly low  
399 income minorities: a randomized dosing trial. *Evid Based Complement Alternat Med.*  
400 2013:658030.  
401
- 402 18. Saper RB, Lemaster C, Delitto A, et al. Yoga, Physical Therapy, or Education for  
403 Chronic Low Back Pain: A Randomized Noninferiority Trial. *Ann Intern Med.*  
404 2017;167(2):85-94.  
405
- 406 19. Wieland LS, Skoetz N, Pilkington K, Vempati R, D'Adamo CR, Berman BM. Yoga  
407 treatment for chronic non-specific low back pain. *Cochrane Database Syst Rev.*  
408 2017;1:CD010671.

## Trial Protocol

- 409  
410 20. Proctor EK, Powell BJ, McMillen JC. Implementation strategies: recommendations for  
411 specifying and reporting. *Implement Sci.* 2013;8:139.  
412
- 413 21. Deyo RA, Dworkin SF, Amtmann D, et al. Report of the NIH Task Force on Research  
414 Standards for Chronic Low Back Pain. *Spine J.* 2014.  
415
- 416 22. Powell BJ, Waltz TJ, Chinman MJ, et al. A refined compilation of implementation  
417 strategies: results from the Expert Recommendations for Implementing Change (ERIC)  
418 project. *Implement Sci.* 2015;10:21.  
419
- 420 23. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation  
421 hybrid designs: combining elements of clinical effectiveness and implementation  
422 research to enhance public health impact. *Med Care.* 2012;50(3):217-226.  
423
- 424 24. Saper RB, Sherman KJ, Delitto A, et al. Yoga vs. physical therapy vs. education for  
425 chronic low back pain in predominantly minority populations: study protocol for a  
426 randomized controlled trial. *Trials.* 2014;15:67.  
427
- 428 25. Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. *Qual Health*  
429 *Res.* 2005;15(9):1277-1288.  
430
- 431 26. Wu, Aimin et al. Global low back pain prevalence and years lived with disability from  
432 1990 to 2017: estimates from the Global Burden of Disease Study 2017. *Annals of*  
433 *translational medicine* vol. 8,6 (2020): 299. doi:10.21037/atm.2020.02.175  
434
- 435 27. Finley CR, Chan DS, Garrison S, Korownyk C, Kolber MR, Campbell S, Eurich DT, Lindblad  
436 AJ, Vandermeer B, Allan GM. What are the most common conditions in primary care?  
437 Systematic review. *Can Fam Physician.* 2018 Nov;64(11):832-840. PMID: 30429181;  
438 PMCID: PMC6234945.  
439
- 440 28. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional,  
441 and national incidence, prevalence, and years lived with disability for 310 diseases and  
442 injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.  
443 *Lancet.* 2016 Oct 8;388(10053):1545-1602. doi: 10.1016/S0140-6736(16)31678-6.  
444 Erratum in: *Lancet.* 2017 Jan 7;389(10064):e1. PMID: 27733282; PMCID: PMC5055577.  
445
- 446 29. Sherry, T. B., Sabety, A., & Maestas, N. (2018). Documented pain diagnoses in adults  
447 prescribed opioids: Results from the national ambulatory medical care survey, 2006-

## Trial Protocol

- 448 2015. *Annals of Internal Medicine*, 169(12), 892–894. [https://doi.org/10.7326/M18-](https://doi.org/10.7326/M18-0644)  
449 0644
- 450 30. Centers for Disease Control and Prevention. 2018 Annual Surveillance Report of Drug-  
451 Related Risks and Outcomes — United States. Surveillance Special Report 2pdf icon.  
452 Centers for Disease Control and Prevention, U.S. Department of Health and Human  
453 Services. Published August 31, 2018.
- 454
- 455 31. Singh, Vanila M., et al. (2019). Pain Management Best Practices Inter-Agency Task Force  
456 Report: Updates, Gaps, Inconsistencies, and Recommendations. Final Report.  
457 Department of Health and Human Services, Washington, DC